Background The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1
nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We …

Background COVID-19 vaccines show excellent efficacy in clinical trials and effectiveness
in real-world data, but some people still become infected with SARS-CoV-2 after vaccination. …

Background The SARS-CoV-2 variant of concern, omicron, appears to be less severe than
delta. We aim to quantify the differences in symptom prevalence, risk of hospital admission, …

Background With the surge of new SARS-CoV-2 variants, countries have begun offering
COVID-19 vaccine booster doses to high-risk groups and, more recently, to the adult population …

Background The SARS-CoV-2 variant B.1.1.7 was first identified in December, 2020, in
England. We aimed to investigate whether increases in the proportion of infections with this …

Worldwide, racial and ethnic minorities have been disproportionately impacted by COVID-19
with increased risk of infection, its related complications, and death. In the initial phase of …

Background: Racial and ethnic minorities have been disproportionately impacted by COVID-19.
In the initial phase of population-based vaccination in the United States (US) and United …

We investigated the effect of sports activity on physically-disabled individuals using behavioral
and electrophysiological techniques. Visual go/no-go discriminative and simple response …

Background Self-reported symptoms during the COVID-19 pandemic have been used to train
artificial intelligence models to identify possible infection foci. To date, these models have …

Background Self-reported symptom studies rapidly increased understanding of SARS-CoV-2
during the COVID-19 pandemic and enabled monitoring of long-term effects of COVID-19 …